August 1, 2018 07:06 AM EDT
Financing
China

As­cle­tis breaks in­to HKEX, briefly ris­ing on hot­ly an­tic­i­pat­ed pub­lic de­but of first biotech

Amber Tong

So how did Hong Kong’s first biotech do on its first day of pub­lic trad­ing?

Ob­servers wast­ed no time not­ing that As­cle­tis Phar­ma — al­lowed on­to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

A service from the Financial Times